Quest Diagnostics Inc (DGX)
136.98
+1.07
(+0.79%)
USD |
NYSE |
Dec 11, 14:14
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 15.40B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -7.85% |
| Valuation | |
| PE Ratio | 20.57 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.680 |
| Price to Book Value | 2.397 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.71 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6615 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 36.60% |
Profile
| Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions. |
| URL | https://www.questdiagnostics.com |
| Investor Relations URL | https://ir.questdiagnostics.com/overview/default.aspx |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 02, 2024 (est.) |
| Last Earnings Release | Oct. 24, 2023 |
| Next Ex-Dividend Date | Jan. 16, 2024 |
| Last Ex-Dividend Date | Oct. 05, 2023 |
Ratings
Profile
| Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions. |
| URL | https://www.questdiagnostics.com |
| Investor Relations URL | https://ir.questdiagnostics.com/overview/default.aspx |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 02, 2024 (est.) |
| Last Earnings Release | Oct. 24, 2023 |
| Next Ex-Dividend Date | Jan. 16, 2024 |
| Last Ex-Dividend Date | Oct. 05, 2023 |